Market Overview

UPDATE: Bank Of America Downgrades MedAssets

Related MDAS
Earnings Scheduled For October 29, 2014
Top 4 NASDAQ Stocks In The Healthcare Information Services Industry With The Highest Revenue

Bank of America downgraded MedAssets (NASDAQ: MDAS) to a Neutral rating upon valuation and assigned a $24 price objective.

Bank of America analyst Robert M. Willoughby said, "The company has benefited from higher demand for its group purchasing and revenue cycle services in the current health care environment, and stronger earnings, coupled with deleveraging in the wake of its Broadlane acquisition in 2010, has pushed ROIC higher at an accelerated clip."

Willoughby continued to cite that MDAS has been trading at an expected P/E multiple of 15.1x for 2015, which is why Willoughby views the stock as fairly valued relative to its historical average of 15.1x.

MedAssets closed Wednesday at $23.41.

Latest Ratings for MDAS

Jan 2015Topeka CapitalInitiates Coverage onBuy
Jan 2015Evercore ISIUpgradesHoldBuy
Jan 2015BairdDowngradesOutperformNeutral

View More Analyst Ratings for MDAS
View the Latest Analyst Ratings

Posted-In: Bank of America Robert M. WilloughbyAnalyst Color Downgrades Analyst Ratings


Related Articles (MDAS)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional